Terms: = Colorectal cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
203 results:
1. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
2. Synergistic antitumor activity between her2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract] [Full Text] [Related]
3. her2 targeted therapy in colorectal cancer: Current landscape and future directions.
Chen N; He L; Zou Q; Deng H
Biochem Pharmacol; 2024 May; 223():116101. PubMed ID: 38442793
[TBL] [Abstract] [Full Text] [Related]
4. her2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
Prete AA; Angerilli V; Bergamo F; Vettore V; De Toni C; Intini R; Cerma K; Ricagno G; Cerantola R; Perissinotto E; De Rosa A; Ceccon C; Gasparello J; Denaro L; D'Amico A; Chioffi F; Carcea E; Fassan M; Lonardi S
Br J Cancer; 2024 May; 130(8):1316-1323. PubMed ID: 38347094
[TBL] [Abstract] [Full Text] [Related]
5. Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for her2-positive tumors.
Zhao S; Qiu Y; Yuan M; Wang Z
Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
[TBL] [Abstract] [Full Text] [Related]
6. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract] [Full Text] [Related]
8. Targeting erbb2/her2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
Zheng-Lin B; Graham RP; Bekaii-Saab TS
Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
[TBL] [Abstract] [Full Text] [Related]
9. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in colorectal cancer and Invasive Breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
10. Calcium-Sensing Receptor Expression in Breast cancer.
Busic-Pavlek I; Dumic-Cule I; Kovacevic L; Milosevic M; Delimar P; Korsa L; Marusic Z; Prutki M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511437
[TBL] [Abstract] [Full Text] [Related]
11. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.
Wang Y; Wei X; Ke B; Liu J; Guo Y; Liu Y; Chen Y; Ding T; Wang Y; Meng B; Sun B; Zang F
Histopathology; 2023 Oct; 83(4):631-646. PubMed ID: 37356975
[TBL] [Abstract] [Full Text] [Related]
12. High preoperative CEA and systemic inflammation response index (C-SIRI) predict unfavorable survival of resectable colorectal cancer.
Cai H; Chen Y; Zhang Q; Liu Y; Jia H
World J Surg Oncol; 2023 Jun; 21(1):178. PubMed ID: 37291634
[TBL] [Abstract] [Full Text] [Related]
13. Combined expression of HIF1α, VEGF and her2 predicts metastasis, relapse and response to combination chemotherapy in colorectal cancer patients.
Jamai D; Kallel I; Mekrazi S; Aloulou S; Walha M; Selmi B; Khabir A
Ann Diagn Pathol; 2023 Oct; 66():152168. PubMed ID: 37290395
[TBL] [Abstract] [Full Text] [Related]
14. Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study.
Tian J; Wang H; Lu C; Liu L; Zhang X; Xie Y; Li R; Lv X; Fu D; Zhang L; Fang X; Wang X; Hu J; Liu X; Huang X; Zhao Q; Luo N; Tang H; Zhong Z; He Y; Li L
Lung Cancer; 2023 Jul; 181():107255. PubMed ID: 37244039
[TBL] [Abstract] [Full Text] [Related]
15. Somatic mutation profiling, tumor-infiltrating leukocytes, tertiary lymphoid structures and PD-L1 protein expression in her2-amplified colorectal cancer.
Liu XT; Kou ZY; Zhang H; Dong J; Zhang JH; Peng YJ; Ma SM; Liang L; Meng XY; Zhou Y; Yang J
PeerJ; 2023; 11():e15261. PubMed ID: 37151285
[TBL] [Abstract] [Full Text] [Related]
16. The Emerging Role of Circulating Tumor DNA in Non-colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
17. [Targeting her2 in colorectal cancer].
Spitzer E; Cervera P; André T; Cohen R
Bull Cancer; 2023 Apr; 110(4):402-411. PubMed ID: 36870811
[TBL] [Abstract] [Full Text] [Related]
18. Circulating Glypican-4 Is a Predictor of 24-Month Overall Survival in Metastatic Breast cancer.
Muendlein A; Heinzle C; Brandtner EM; Leiherer A; Drexel H; Dechow T; Decker T
Oncol Res Treat; 2023; 46(4):151-156. PubMed ID: 36750040
[TBL] [Abstract] [Full Text] [Related]
19. Driver and targetable alterations in Chinese patients with small bowel carcinoma.
Li J; Li X; Dong N; Yan S; Jing C; Ma T; Li W; Zhang C; Cai Y; Deng W
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6139-6150. PubMed ID: 36680582
[TBL] [Abstract] [Full Text] [Related]
20. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract] [Full Text] [Related]
[Next]
